Prospective Biomarker Study in Advanced RAS Wild‐Type Colorectal Cancer: POSIBA Trial (GEMCAD 10‐02)

BACKGROUND. RAS testing is used to select patients with anti‐epidermal growth factor receptor (EGFR) therapies sensitivity in metastatic colorectal cancer (mCRC). However, other biomarkers such as BRAF, PIK3CA/PTEN, and p‐IGF‐1R+/MMP7+ (double positive [DP] phenotype) have not been prospectively ass...

Descripción completa

Detalles Bibliográficos
Autores principales: García‐Albéniz, Xabier, Alonso, Vicente, Escudero, Pilar, Méndez, Miguel, Gallego, Javier, Rodríguez, Jose Ramon, Salud, Antonia, Fernández‐Plana, Julen, Manzano, Hermini, Zanui, Montserrat, Falcó, Ester, Feliu, Jaime, Gil, Mireia, Fernández‐Martos, Carlos, Bohn, Uriel, Alonso, Carmen, Calderero, Verónica, Rojo, Federico, Cuatrecasas, Miriam, Maurel, Joan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Gastrointestinal Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853109/
https://www.ncbi.nlm.nih.gov/pubmed/31235483
http://dx.doi.org/10.1634/theoncologist.2018-0728

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853109/
https://www.ncbi.nlm.nih.gov/pubmed/31235483
http://dx.doi.org/10.1634/theoncologist.2018-0728

Ejemplares similares